GU Cancers 2024 | Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible mUC

Rohit Jain, MD, MPH, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, comments on results from the Phase II PemCab trial (NCT03534804) of pembrolizumab and cabozantinib as a first-line treatment in patients with metastatic urothelial carcinoma (mUC). A promising overall response rate (ORR) and complete response were recorded in patients. Adverse events were additionally manageable and this combination therapy demonstrated efficacy in cisplatin-ineligible patients, suggesting a potential alternative for this population. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.